Recent Company News

• 04:38 PM ET Dec 03, 2025
  

  Chugai Pharmaceutical initiated outperform at CLSA (¥8213.0000, 0)

• 01:45 AM ET Nov 26, 2025
  

  Renalys Pharma's phase 3 study topline results confirm efficacy of sparsentan in Japanese IgA nephropathy patients

• 09:01 AM ET Nov 25, 2025
  

  Sarepta announces approval to begin ENDEAVOR Cohort 8 to evaluate enhanced immunosuppression regimen as part of ELEVIDYS gene therapy for non-ambulant individuals with Duchenne ($18.91, 0.00)

• 02:11 AM ET Nov 20, 2025
  

  Chugai Pharmaceutical obtained Japan MHLW approval for FoundationOne CDx Cancer Genomic Profile on 3-Oct (¥8278.0000, 0)

• 01:01 AM ET Nov 19, 2025
  

  European Commission approves Roche's Lunsumio subcutaneous for relapsed or refractory follicular lymphoma (CHF 306.70, 0.00)

• 05:10 AM ET Nov 16, 2025
  

  Chugai Pharmaceutical upgraded to outperform from neutral at Daiwa (¥8113.0000, 0)

• 02:18 PM ET Nov 06, 2025
  

  FDA awards second batch of CNPVs, six more including two obesity drugs

• 04:56 AM ET Oct 24, 2025
  

  Chugai Pharmaceutical to buy Renalys Pharma for ¥15.00B in cash plus amount reflecting price adjustment; to pay seller up to ¥16.00B in milestone payments (¥6935.0000, 0)

• 04:43 AM ET Oct 24, 2025
  

  StreetAccount Metrics Recap - Chugai Pharmaceutical Q3 Earnings (¥6935.0000, 0)

• 04:19 AM ET Oct 24, 2025
  

  Chugai Pharmaceutical reports Q3 core net income attributable ¥126.5B vs FactSet ¥118.02B (¥6935.0000, 0)